Enzyvant is now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies. Follow us at?Sumitomo Pharma America, Inc.
Enzyvant
生物技术研究
Cambridge，Massachusetts 7,705 位关注者
is part of Sumtiomo Pharma America as of July 2023
关于我们
This page is no longer active or monitored.?We are now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow us! This page is no longer active or monitored.??? ???? ???? ? ==== About Enzyvant Enzyvant is a biopharmaceutical company making life-altering impact for people affected by rare disease, where communities are small, and the human need is immense. Enzyvant partners with these communities to accelerate development of transformative medicines, collaborating with academia, industry, physician associations, advocacy groups and government, because strong relationships make bold science possible. Enzyvant has capabilities spanning non-clinical and clinical development and commercialization and is developing in-house manufacturing. The company delivered one of the first Regenerative Medicine Advanced Therapy products and makes promising advances against some of the greatest challenges in immunology and cardiopulmonology. For more information about Enzyvant, visit www.Enzyvant.com.
- 网站
-
https://www.enzyvant.com
Enzyvant的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2016
- 领域
- biotechnology和congenital athymia